Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma / 中华肝脏病杂志
Chinese Journal of Hepatology
;
(12): 834-837, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-801304
ABSTRACT
Hepatocellular carcinoma (HCC) has a high incidence and mortality rate in China, and is the worst-than-expected cancer management disease in all provinces of the country. In recent years, systemic drug therapy for HCC has developed rapidly, especially molecular targeted drugs and immune checkpoint blocker being the most prominent. Molecular targeted drugs and immune checkpoint blocker have achieved some progress in the treatment of advanced HCC, but they still have many problems and challenges. This paper briefly introduces the latest advances of drug therapy for advanced HCC.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Hepatology
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS